Extramedullary immunoprivileged sites as a niche for residual and relapsed FLT3-ITD mutated AML: an unmet clinical
Philip D Tracy1,2, Ruben Delgado3, Ahmad Al-Akdi3
1Division of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA.
Leukemia & Lymphoma
|November 28, 2024
Abstract
No abstract available in PubMed .


